Literature DB >> 33553010

Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress.

Fariba Aghahoseini1, Alireza Alihemmati1,2, Leila Hosseini3, Reza Badalzadeh3,4,5.   

Abstract

PURPOSE: Vildagliptin has been shown to prevent microvascular complications during diabetes. The aim of this research was to evaluate the antioxidant effects of vildagliptin in diabetic nephropathy.
METHODS: The diabetes was induced in the animals by high-fat diet and intraperitoneal injection of 35 mg/kg streptozotocin. After diagnosis of diabetes, the vildagliptin (6 mg/kg/day) was orally administered for one month. The biochemical parameters of blood urea nitrogen, creatinine, insulin, and serum albumin were measured. The levels of stress oxidative markers were detected using spectrophotometry.
RESULTS: Treatment with vildagliptin significantly diminished blood glucose, oxidative stress, and reduced creatinine as well as increased insulin secretion. In addition, the vildagliptin improved renal glomerular and tubule interstitial damages and reduced vascular lesions.
CONCLUSIONS: The treatment with vildagliptin can be useful in controlling the renal complications of type 2 diabetes mellitus through inhibiting lipid peroxidation and increasing the antioxidant enzymes. © Springer Nature Switzerland AG 2020.

Entities:  

Keywords:  Kidney; Nephropathy; Oxidative stress; Type 2 diabetes; Vildagliptin

Year:  2020        PMID: 33553010      PMCID: PMC7843866          DOI: 10.1007/s40200-020-00548-7

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  30 in total

Review 1.  Oxidative stress and diabetes mellitus.

Authors:  Hui Yang; Xun Jin; Christopher Wai Kei Lam; Sheng-Kai Yan
Journal:  Clin Chem Lab Med       Date:  2011-08-03       Impact factor: 3.694

2.  DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

Authors:  Lorenzo L F Glorie; Anja Verhulst; Veerle Matheeussen; Lesley Baerts; Joanna Magielse; Nina Hermans; Patrick C D'Haese; Ingrid De Meester; Annelies De Beuf
Journal:  Am J Physiol Renal Physiol       Date:  2012-06-20

3.  Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

Authors:  B F Burkey; X Li; L Bolognese; B Balkan; M Mone; M Russell; T E Hughes; P R Wang
Journal:  J Pharmacol Exp Ther       Date:  2005-07-18       Impact factor: 4.030

Review 4.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 5.  Animal models in type 2 diabetes research: an overview.

Authors:  K Srinivasan; P Ramarao
Journal:  Indian J Med Res       Date:  2007-03       Impact factor: 2.375

Review 6.  The biology of incretin hormones.

Authors:  Daniel J Drucker
Journal:  Cell Metab       Date:  2006-03       Impact factor: 27.287

Review 7.  Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

Authors:  Julio Rosenstock; Bernard Zinman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2007-04       Impact factor: 3.243

8.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

Authors:  Loredana Farilla; Hongxiang Hui; Cristina Bertolotto; Elizabeth Kang; Angela Bulotta; Umberto Di Mario; Riccardo Perfetti
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

9.  Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study.

Authors:  Nam Hoon Kim; Dong Lim Kim; Kyeong Jin Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Sin Gon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2017-06

10.  Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.

Authors:  Mohammed I Hawa; Hubert Kolb; Nanette Schloot; Huriya Beyan; Stavroula A Paschou; Raffaella Buzzetti; Didac Mauricio; Alberto De Leiva; Knud Yderstraede; Henning Beck-Neilsen; Jaakko Tuomilehto; Cinzia Sarti; Charles Thivolet; David Hadden; Steven Hunter; Guntram Schernthaner; Werner A Scherbaum; Rhys Williams; Sinead Brophy; Paolo Pozzilli; Richard David Leslie
Journal:  Diabetes Care       Date:  2012-12-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.